Cutaneous leishmaniasis (CL) is a significant public health problem caused by different
species of Leishmania parasites. Due to low skin permeability, the development of an …

Cutaneous leishmaniasis (CL) is an infectious, parasitic disease caused by the protozoan
Leishmania. Amphotericin B (AMB) is a macrolide polyene antibiotic presenting potent …

Current therapeutic options against cutaneous leishmaniasis are plagued by several
weaknesses. The effective topical delivery of an antileishmanial drug would be useful in …

The development of an effective amphotericin B (AmB) topical formulation to replace the
systemically toxic injections currently used in cutaneous leishmaniasis (CL) treatment is …

Amphotericin B (AmB) is an antifungal and antiparasitic agent that is the main drug used for
the treatment of mycoses infections and leishmaniasis. However, its high toxicity and side …

Biocompatible and biodegradable materials have been used for fabricating polymeric
microneedles to deliver therapeutic drug molecules through the skin. Microneedles have …

Topical treatment of cutaneous leishmaniasis represents an exciting alternative for reducing
toxicity associated with parenteral administration of conventional amphotericin B. This work …

The development of dissolving microneedles (DMN) is one of the advanced technologies in
transdermal drug delivery systems, which precisely deliver the drugs through a rapid …

The major goal of this work was to design a new nanoparticle drug delivery system for
desoxycholate amphotericin B (D-AMB), based on controlled particle size, looking for the …

Fungal infections affect millions of people globally and are often unreceptive to conventional
topical or oral preparations because of low drug bioavailability at the infection site, lack of …